Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Australia unveiled a major investment to advance brain cancer clinical research, spotlighting landmark immunotherapy breakthroughs and patient-focused innovation
Megafunding rounds and regulatory momentum reshaped the biotech investment landscape, signaling growing confidence in transformative clinical innovation.
Japanese pharma giant Taiho invests up to $1.14 billion in Swiss innovation, expanding its portfolio in antibody-drug conjugates …
Regeneron and Sanofi bolster their immunology-focused portfolios by acquiring global rights to a promising monoclonal antibody targeting autoimmune …
Amgen advances clinical research with promising data in cardiovascular disease and cancer, reinforcing its commitment to innovation and …
Major pharma players unveil significant clinical trial progress and strategic collaborations targeting obesity and cardiovascular health.
Recent developments underscore innovation in rare diseases and artificial intelligence, reshaping treatment paradigms and accelerating drug development.
March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
Already a subscriber? Log in